Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC